Pharmaceutical

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

Five things for pharma marketers to know: Thursday, January 22

Five things for pharma marketers to know: Thursday, January 22

Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.

Novartis psoriasis drug approval could upend market

Novartis psoriasis drug approval could upend market

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

Nurse practitioner workforce has just about doubled

Marketers may want to dust off plans to create NP-centric materials.

Sandoz gets ready to make the biosimilar case with oncologists

Sandoz gets ready to make the biosimilar case with oncologists

Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.

J&J Q4 sales slip, but year finishes up 4.2%

J&J Q4 sales slip, but year finishes up 4.2%

Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.